Jessica Menis

👉How do we combine #TKIs with various forms of #radiotherapy in #NSCLC? When should we interrupt or modify their dose? 💡Just out in @ESMO_Open a collaborative effort between @myESMO and @estro with recommendations for #EGFR, #ALK and #BRAF/MEK inhinitors Happy to have contributed to this practical guide for clinicians Link to the article: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2… #LCSM @IASLC @ASCO @OncoAlert @OncBrothers @oncodaily @MedscapeOnc @VJOncology @Peerview @EGFRResisters @EgfrUk @EGFRmNSCLC @YoungLungCancer @ALKPositiveinc

New LCC episode! 🎙️ Dr. Steven Liu hosts a virtual tumor board with @caliraf and @JessicaMenis on current treatment strategies for extensive-stage #SCLC, including recent updates shaping today’s care decisions. Listen: bit.ly/461LUWN #LungCancerConsidered #LungCancer

From #ICTD26: New therapeutic insights in #SCLC: ➡️NOTCH deregulation and ASCL1/DLL3 upregulation define neuroendocrine transcription ➡️ADCs targeting DLL3/B7-H3/TROP2/SEZ6 in ph3 trials ➡️Algorithm evolving, wait for the new @myESMO SCLC guidelines! #some #LCSM

@g_mountzios @ElinardouHelena @StephenVLiu @DrJNaidoo @delvysra @g_mountzios our lead !!! 👏🏻👏🏻👏🏻

A superb session on the 2nd day of #ITCD26 focusing on #SCLC chaired by Rolf Stahel and @ElinardouHelena . Great to contribute alongside great colleagues and friends @StephenVLiu and @DrJNaidoo , followed be brainstorming discussions. Big 🙏to great hosts @delvysra @rosariogarc #LCSM #some @OncBrothers @OncoAlert @HeSMO_X @Women4Oncology

📚 A week that makes a real difference. Step back, refine your clinical trial protocol, receive continuous expert feedback and build lasting scientific connections. 📅 13–18 June 2026 ⏳ Applications close 30 January 2026 👉 Apply now: event.eortc.org/mccr2026/appli…

Report @JTOonline on 3L treatment patterns in SCLC from the German CRISP Registry (AIO-TRK-0315). Note that most do not receive 3L. In this cohort, 1L therapy typically carbo, etop, atezolizumab and 2L was topotecan / CAV. 3L options were paclitaxel (22%), topotecan (22%).

🔎What can you expect from the #MCCRWorkshop? You will spend a full week improving your clinical trial protocol with expert support in a collaborative, small-group environment. 📅 13–18 June 2026 Apply: event.eortc.org/mccr2026/appli… #clinicaltrialdesign #clinicalresearch

#ESMOAsia2025 Lung Orals🔥 Ph II Trispecific T-cell Engager Alveltamig in pre-Tx SCLC: - 60pts - ORR 53.3% (10mg), 56.7% (30mg), near 60% still responding at 9m - TRAEs: pyrexia, CRS, vomiting, no g3+ CRS (10mg), no ICANS Promising #ESMOAmbassadors @myESMO @OncoAlert #LCSM

Controversies and open questions in SCLC: PS2, PCI, biomarkers… have you ever thought about sequencing SCLC? AMAZING!!! #ESMOPreceptorshipAsia @JordiRemon @myESMO

Celebrating time together at the IX Conferenza Oncologia Polmonare faculty dinner in Bari with @galetta2 @NReguart @marialuciareale @JessicaMenis @g_mountzios @Giangidegennaro

Amazing hospitality and welcome reception by @galetta2 in beautiful Bari for the 9th lung cancer conference Great to catch up with friends and colleagues around the world!! Looking forward to our brainstorming sessions tomorrow!! #some #lcsm #bari

Thank you #ESMO25 for the science, the education, the partnerships but most importantly for this human bonding of people who share a common passion to improve cancer care worldwide🌏🌍🌎🏆

Coming together with dear friends at #ESMO25 in Berlin! @MartinReck2 @JessicaMenis @CharuAggarwalMD @MLJohnsonMD2 @HwakeleeMD @DrJNaidoo @PatelOncology @JordiRemon @DrSanjayPopat @LuisPaz_Ares @PrelajArsela @marinagarassino @LudaBazhenovaMD @FedericoCappuz1 @a_dingemans

#WCLC25 : Professor Ahn presenting the much awaited results of Ifinatamab DXd ( iDXd) in pretreated pts with #SCLC : ✅ ORR=48.2% in ITT, 56.3% in 2L, 51% in CFTI<90d ✅ mPFS=4.9m, DoR=5.3m, OS=10.3m ✅ mOS=12m for 2L pts! ✅ ILD in 12.4% Ph3 IDeate-Lung02 ongoing! @IASLC @OncBrothers @OncoAlert @VJOncology

So great catching up with friends and colleagues @GustaveRoussy at #WCLC25 @IASLC

#WCLC25 Presidential FLAURA2 OS in 1L EGFR+ NSCLC: - mOS 47.5m v 37.6m (HR 0.77 p=0.02) - duration of osi 30.5m on osi+chemo v 21.2m osi- combo delays acq resistance? - 72% got 2L chemo- does this add ~9m? - all subgrps benefit (?BM, ?co-mtns) Congrats @dplanchard @iaslc #LCSM

#WCLC25 Presidential I @JordiRemon delivers an exceptional discussion of ACROSS2, key themes: - trial not significant (?) preplanned HR 0.49 - are TPS genes prognostic/predictive - are tumors with TPS genes, destined for histologic transformation? @IASLC @GustaveRoussy #LCSM

⭐ #WCLC25 Presenter Spotlight: Enrica Capelletto, MD, PhD, aims to raise awareness about alternatives to conventional smoking. 🚭 Learn more in ILCN: ilcn.org/other-than-cig… #LCSM

EDU session at #WCLC25 Advancing EGFR mutant NSCLC opportunities, sequencing approaches, LMD & SNC disease by @JessicaMenis @aaronctan @rossana_rm @HelenaYu923 @EGFRResisters